Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer

Lung Cancer

Volumn 39, Issue 3, 2003, Pages 331-338

  De Marinis, Filippo ^a   Migliorino, Maria Rita ^a   Paoluzzi, Luca ^a   Portalone, Luigi ^a   Ariganello, Ottaviano ^a   Cortesi, Enrico ^b   Gamucci, Teresa ^c   Gasperoni, Silvia ^d   Cipri, Antonino ^a   Martelli, Olga ^a   Nelli, Fabrizio ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Umberto I Hospital   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cisplatin; Etoposide; Extensive stage disease; Gemcitabine; Limited stage disease; Phase I II trial; Small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DISEASE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME;

EID: 0037374521     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00500-7     Document Type: Article

References (27)

1. Bunn P.A. Jr, Carney D.N. Overview of chemotherapy for small cell lung cancer. Semin. Oncol. 24:(2 Suppl. 7):1997;69-74.
2. Johnson D.H. Management of small cell lung cancer: current status of the art. Chest. 116:1999;525-530.
3. Zochbauer-Muller S., Pirker R., Huber H. Treatment of small cell lung cancer patients. Ann. Oncol. 10:(Suppl. 6):1999;83-91.
4. Storniolo A.M., Allerheiligen S., Pearce H.L. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin. Oncol. 24:(2 Suppl. 7):1997;2-7.
5. Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active new agent in previously untreated extensive-stage small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 5:1994;283-285.
6. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:(4 Suppl. 11):1995;72-79.
7. Rosell R., Tonato M., Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin. Oncol. 25:(4 Suppl. 9):1998;27-34.
8. van Moorsel C.J., Pinedo H.M., Veerman G., et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem. Pharmacol. 57:1999;407-415.
9. Rassmann I., Thodtmann R., Depenbrock H., et al. Gemcitabine and etoposide in small cell lung cancer: phase I and II trials. Semin. Oncol. 24:(2 Suppl. 7):1997;75-78.
10. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
11. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
12. Ihde D.C., Mulshine J.L., Kramer B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12:1994;2022-2034.
13. Murray N., Coy P., Pater J.L., et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 11:1993;336-344.
14. Aisner J. Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J. Clin. Oncol. 14:1996;658-665.
15. Ettinger D.S. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin. Oncol. 28:(2 Suppl. 4):2001;27-29.
16. Stewart D.J., Earle C., Cormier Y., et al. Phase I study of cisplatin, etoposide and gemcitabine in small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 16:1997;. abstr. 1627.
17. Glisson B.S., Kurie J.M., Perez-Soler R., et al. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J. Clin. Oncol. 17:1999;2309-2315.
18. Kelly K., Bunn P.A., Lovato L., et al. Final results from Southwest Oncology Group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients with extensive stage small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;. abstr. 1923.
19. Mavroudis D., Papadakis E., Veslemes M., et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann. Oncol. 12:2001;463-470.
20. Hainsworth J.D., Gray J.R., Stroup S.L., et al. Paclitaxel, carboplatin and extended-schedule etoposide in the treatment of small-cell lung cancer: comparision of sequential phase II trials using different dose-intensities. J. Clin. Oncol. 15:1997;3464-3470.
21. Hainsworth J.D., Burris H.A. III, Greco F.A. Paclitaxel-based three-drug combinations for the treatment of small-cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Semin. Oncol. 28:(2 Suppl. 4):2001;43-47.
22. Gatzemeier U., von Pawel J., Macha H., et al. A phase III trial of taxol, etoposide phosphate and carboplatin (TEC) versus carboplatin, etoposide phosphate and vincristine (CEV) in previously untreated small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;. abstr. 1889.
23. Bunn P.A., Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 117:(Suppl. 1):2000;138-143.
24. Kelly K. New chemotherapy agents for small cell lung cancer. Chest. 117:(Suppl. 1):2000;156-162.
25. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346:2002;85-91.
26. Israel V.P., Chansky K., Gandara D. Southwest Oncology Group trial (SWOG) S9718: a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer (E-SCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;. abstr. 1262.
27. Thomas P., Castelnau O., Paillotin D., et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J. Clin. Oncol. 19:2001;1320-1325.